Two-Drug Combination Approved for Lung Cancers with BRAF Mutations

FDA approved the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®) for the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.

Cancer Currents: An NCI Cancer Research Blog